As Shkre­li at­tor­ney Greebel heads to his own prison cell, the bad boy of biotech is still skew­er­ing en­e­mies in new ...

7 years ago
People

Ab­b­Vie, Sanofi-backed Prin­cip­ia of­fers an $86M IPO af­ter burn­ing through $148M for pipeline work

7 years ago
Financing

Har­bour Bio­Med jumps in­to the crowd­ed PD-1/L1 race, look­ing to take a Chi­nese as­set glob­al as check­point pipeline ...

7 years ago
R&D
China

Roche picks up a speedy nod in Chi­na as reg­u­la­tors fol­low through on plans for a fast 48 new drug OKs

7 years ago
China
Pharma

Pfiz­er spells out PhI­II ta­la­zoparib da­ta in NE­JM ar­ti­cle; Tolero teams up with Ab­b­Vie for AML com­bo

7 years ago
News Briefing

Out­spo­ken re­searcher Pe­ter Bach urges CMS to con­sid­er ways of bring­ing down CAR-T prices — and of­fers a few ...

7 years ago
Pharma

John Kaiser finds next CEO role at Duke spin­out Evecx­ia; Im­muno­core vet Namir Has­san moves to I/O biotech Zel­lu­na

7 years ago
Peer Review

Just a few days af­ter a stum­ble, FDA OKs 12-week dose for Eylea as Re­gen­eron braces for No­var­tis at­tack

7 years ago
Pharma

In a land­mark OK, FDA green-lights Bris­tol-My­er­s' Op­di­vo for a niche group of metasta­t­ic lung can­cer pa­tients

7 years ago
Pharma

FDA, NIH look to stream­line over­sight of gene ther­a­pies

7 years ago
Pharma
Cell/Gene Tx

No­vo Nordisk buys uni­ver­si­ty spin­out Ziy­lo — adding a po­ten­tial rem­e­dy for hy­po­glycemia to its di­a­betes pipeline

7 years ago
Deals

Months af­ter team­ing up on RTK in­hibitor Lenvi­ma, Ei­sai/Mer­ck win new FDA OK in liv­er can­cer

7 years ago
Pharma

Af­ter a years-long de­lay, FDA ap­proves first gener­ic ver­sions of EpiPen

7 years ago
Pharma

Sarep­ta CEO Doug In­gram buys $2M batch of his biotech's stock; Ex­press Scripts ex­plor­ing ex­clu­sive gene ther­a­py deals

7 years ago
News Briefing

For­mer head of Chi­na's FDA boot­ed in wake of sear­ing vac­cine scan­dal as lead­ers im­pose 'se­vere pun­ish­men­t'

7 years ago
R&D
China

No more hands-off Roche su­per­vi­sion? Genen­tech brings out the axe, slash­ing 223 HQ staffers 'across de­part­ments'

7 years ago
R&D
Pharma

'Gap years' are for adults, too: Ex-Foun­da­tion ex­ec Steve Kaf­ka joins Third Rock af­ter glo­be­trot­ting break

7 years ago
People

A 'high-risk, high-re­ward' ef­fort on NGF pain med fas­inum­ab by Re­gen­eron, Te­va clears a re­vised PhI­II -- se­ri­ous ...

7 years ago
R&D

Bio­haven steps up big clin­i­cal plans for its re­for­mu­lat­ed ALS gener­ic — now al­so aimed at anx­i­ety

7 years ago
R&D

Pfiz­er hits the gas ped­al in the mR­NA flu vac­cine de­vel­op­ment race, ink­ing a $425M in­vest­ment pact with BioN­Tech

7 years ago
Pharma

Ar­mored CAR-Ts? Memo­r­i­al Sloan Ket­ter­ing en­gi­neers CAR-T loaded with check­point in­hibitors

7 years ago
Discovery

Let's go to Chi­na: Join End­points in Shang­hai for the first US-Chi­na Bio­phar­ma In­no­va­tion & In­vest­ment Sum­mit — ...

7 years ago
Publisher's note
China

Der­ma­tol­ogy biotech Blue­ber­ry Ther­a­peu­tics banks $12M Se­ries B — and new part­ners in Asia

7 years ago
Financing

Black­stone in­vests $400M in one of Chi­na's fast-grow­ing phar­ma com­pa­nies; CVS sets up an ICER-based for­mu­la­ry

7 years ago
News Briefing
First page Previous page 1017101810191020102110221023 Next page Last page
A service from the Financial Times